What is the protocol for initiating high‑dose insulin euglycemia therapy in a patient with amlodipine and/or atenolol overdose presenting with hypotension?

High-Dose Insulin Euglycemia Therapy Protocol

For amlodipine and/or atenolol overdose with hypotension, initiate high-dose insulin therapy immediately at 1 U/kg bolus followed by 1-10 U/kg/hour continuous infusion, along with concurrent dextrose supplementation to maintain euglycemia, either as first-line therapy or in conjunction with vasopressors. 1

Initiation Protocol

Immediate Steps

Start insulin aggressively:

• Bolus: 1 U/kg regular insulin IV push 1, 2
• Continuous infusion: Begin at 1 U/kg/hour, titrate up to 10 U/kg/hour based on hemodynamic response 1, 2
• Some case reports document successful use up to 22 U/kg/hour without significant adverse events 2

Concurrent dextrose administration:

• Start dextrose 10% infusion at 0.5 g/kg/hour (approximately 50-100 mL/hour for average adult) 2, 3
• Adjust rate to maintain blood glucose 100-200 mg/dL
• May require higher concentrations (D25% or D50%) if fluid overload is a concern 4

Monitoring Requirements

Glucose monitoring:

• Check blood glucose every 15-30 minutes initially
• Once stable, check hourly during insulin infusion
• Continue monitoring for 24 hours after insulin discontinuation 2

Electrolyte monitoring:

• Check potassium every 1-2 hours initially
• Anticipate hypokalemia from intracellular potassium shift (not true depletion) 2
• Supplement potassium to maintain >3.5 mEq/L

Hemodynamic monitoring:

• Continuous arterial blood pressure monitoring
• Expect improvement within 30 minutes to 3 hours of initiation 3, 5, 6

Rationale for Both Amlodipine and Atenolol

The 2023 AHA guidelines provide Class 1, Level B-NR recommendation for high-dose insulin in both β-blocker (atenolol) and calcium channel blocker (amlodipine) poisoning 1. This is the strongest recommendation level available.

For atenolol (β-blocker):

• High-dose insulin improves inotropy in cardiogenic shock
• Shows favorable outcomes with lower rates of vasoconstrictive complications compared to vasopressor-only therapy 1
• Should be administered "refractory to or in conjunction with vasopressor therapy" 1

For amlodipine (calcium channel blocker):

• High-dose insulin is a Class 1, Level B-NR recommendation for hypotension 1
• Mechanism includes increased inotropy, enhanced intracellular glucose transport, and vascular effects 2
• Case reports demonstrate dramatic improvement within 30 minutes of initiation 3, 5

Concurrent Therapies

Vasopressors (Class 1 recommendation for both):

• Norepinephrine is most commonly used (doses up to 100 μg/min documented) 1
• Initiate early as they act quickly while insulin takes effect 1
• High-dose insulin allows for vasopressor weaning and reduces ischemic complications 1

Calcium supplementation (for amlodipine):

• Calcium chloride or gluconate boluses (Class 2a recommendation) 1
• Target ionized calcium up to twice normal 1
• Most effective when combined with high-dose insulin 3, 7

Glucagon (for atenolol):

• Class 2a recommendation: bolus followed by continuous infusion 1
• Less effective than high-dose insulin but reasonable adjunct 1

Atropine:

• May be reasonable for bradycardia (Class 2b for β-blockers, Class 2a for CCBs) 1
• Often ineffective as monotherapy 1

Critical Pitfalls to Avoid

Do not delay insulin therapy:

• Animal studies show insulin superior to calcium, glucagon, epinephrine, and vasopressin for survival 2
• Early initiation (within 8 hours) associated with better outcomes 6
• The 2023 AHA guidelines explicitly state insulin can be given "in conjunction with" (not just refractory to) vasopressors 1

Do not underdose insulin:

• Initial protocols used 0.5 U/kg/hour cautiously, but experience shows 1-10 U/kg/hour is safe and more effective 2
• Dose-dependent hemodynamic improvement documented 3
• Titrate aggressively based on blood pressure response

Do not stop dextrose prematurely:

• Hypoglycemia risk persists up to 24 hours after insulin discontinuation 2
• Maintain dextrose infusion during insulin weaning
• No standardized discontinuation protocol exists—wean gradually while monitoring glucose closely 4

Avoid intravenous lipid emulsion:

• Class 3 (No Benefit) recommendation for β-blocker poisoning 1
• Not recommended for routine CCB poisoning; may increase GI absorption of lipophilic drugs 1

Special Considerations for Atenolol

Hemodialysis:

• Class 2b recommendation: "may be reasonable" for life-threatening atenolol poisoning 1
• Atenolol is water-soluble and dialyzable 8
• Consider for refractory cases, especially with renal impairment 7
• Continuous veno-venous hemodialysis (CVVHD) successfully used in combined overdose 7

Rescue Therapies for Refractory Shock

VA-ECMO (Class 2a recommendation):

• Reasonable for cardiogenic shock refractory to pharmacological interventions 1, 9
• Case reports demonstrate life-saving potential 1, 9
• Requires experienced center with ECMO capability

Escalating insulin doses:

• For periarrest patients, consider incremental increases up to 10 U/kg/hour 9
• Case reports document safe use of unconventionally high doses (>10 U/kg/hour) with close monitoring 4

The evidence strongly supports high-dose insulin euglycemia therapy as superior to conventional treatments for both amlodipine and atenolol overdose, with the 2023 AHA guidelines providing the highest level of recommendation for both drug classes. The key to success is early, aggressive dosing with meticulous glucose and electrolyte monitoring.